SCHEMBL15419965

SCHEMBL15419965

COCCS(=O)(=O)NC1CCOCC1COc1ccc(-n2cc(Cl)cn2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 5/20 0.36
HRH3 Q9Y5N1 1/20 0.33
KAT5 Q92993 1/20 0.33
RIPK2 O43353 1/20 0.32
SMO Q99835 1/20 0.32
MKNK1 Q9BUB5 1/20 0.32
GCGR P47871 1/20 0.32
EGFR P00533 1/20 0.31
FGFR1 P11362 1/20 0.31
KDR P35968 1/20 0.31
APLNR P35414 4/20 0.31
CYP17A1 P05093 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP21A2 P08686 1/20 0.31
CYP19A1 P11511 1/20 0.31
CYP11B1 P15538 1/20 0.31
AXL P30530 1/20 0.31
PDE1A P54750 1/20 0.30
PDE1B Q01064 1/20 0.30
PDE1C Q14123 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15441451 1.00 CHRM1 (0.36) CHRM1HRH3KAT5RIPK2SMO
SCHEMBL15420340 0.91 CHRM1 (0.34) CHRM1HRH3KAT5RIPK2MKNK1
SCHEMBL15420165 0.91 CHRM1 (0.34) CHRM1HRH3KAT5RIPK2MKNK1
SCHEMBL15420468 0.91 CHRM1 (0.34) CHRM1HRH3KAT5RIPK2MKNK1
SCHEMBL15420710 0.89 CHRM1 (0.33) CHRM1HRH3KAT5RIPK2MKNK1
SCHEMBL15441955 0.89 CHRM1 (0.33) CHRM1HRH3KAT5RIPK2MKNK1
SCHEMBL15420115 0.88 CHRM1 (0.35) CHRM1HRH3KAT5RIPK2MKNK1
SCHEMBL15420689 0.88 CHRM1 (0.35) CHRM1HRH3KAT5RIPK2MKNK1
SCHEMBL15420318 0.88 CHRM1 (0.35) CHRM1HRH3KAT5RIPK2MKNK1
SCHEMBL15441455 0.86 CHRM1 (0.32) CHRM1HRH3KAT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 CHRM1 227/4885HRH3 1365/4885KAT5 2329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.